Martin Capital Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-41,064
Closed -$3.33M 70
2023
Q4
$3.33M Sell
41,064
-447
-1% -$34.8K 1.36% 37
2023
Q3
$3.11M Buy
41,511
+514
+1% +$39.5K 1.31% 41
2023
Q2
$3.16M Sell
40,997
-709
-2% -$56.5K 1.28% 42
2023
Q1
$3.46M Sell
41,706
-25,531
-38% -$2.11M 1.44% 39
2022
Q4
$5.77M Buy
67,237
+1,360
+2% +$108K 2.38% 18
2022
Q3
$4.06M Buy
65,877
+2,327
+4% +$147K 1.88% 29
2022
Q2
$3.93M Buy
63,550
+1,693
+3% +$105K 1.86% 29
2022
Q1
$3.68M Buy
61,857
+2,636
+4% +$168K 1.68% 33
2021
Q4
$4.3M Buy
59,221
+645
+1% +$44.4K 2.03% 25
2021
Q3
$4.09M Buy
58,576
+452
+0.8% +$31.8K 2.07% 27
2021
Q2
$4M Buy
58,124
+989
+2% +$66K 2.03% 27
2021
Q1
$3.69M Buy
57,135
+9,222
+19% +$595K 1.96% 26
2020
Q4
$2.79M Sell
47,913
-884
-2% -$53.3K 1.63% 33
2020
Q3
$3.08M Sell
48,797
-406
-0.8% -$28.2K 2.06% 25
2020
Q2
$3.79M Sell
49,203
-10,793
-18% -$827K 2.66% 18
2020
Q1
$4.49M Sell
59,996
-450
-0.7% -$31.1K 3.42% 5
2019
Q4
$3.93M Buy
60,446
+25,817
+75% +$1.68M 2.32% 22
2019
Q3
$2.19M Buy
+34,629
New +$2.26M 1.48% 36

Other funds holding GILD

Martin Capital Partners's GILD Position: Q1 2024 in Review

Martin Capital Partners sold out of Gilead Sciences (GILD) in Q1 2024, closing a stake of 41,064 shares — an estimated $3.33M sold.

Martin Capital Partners first reported a position in GILD in Q3 2019 and held it in 18 quarters. The position peaked at $5.77M in Q4 2022. 1,721 funds tracked by Wall St. Rank hold GILD as of Q1 2024.

  • Martin Capital Partners reported no remaining Gilead Sciences position as of Q1 2024 after selling out during the quarter.
  • Martin Capital Partners sold 41,064 Gilead Sciences shares in Q1 2024, an estimated $3.33M.
  • Martin Capital Partners first reported a position in Gilead Sciences in Q3 2019 and held it in 18 quarters.
  • Martin Capital Partners's Gilead Sciences position peaked at $5.77M in Q4 2022.
  • 1,721 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.

Based on Martin Capital Partners's 13F filing for Q1 2024, filed 5 Apr 2024.